Compare McKesson Corporation (MCK) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Xylem, Inc. — how do they compare? McKesson Corporation trades at $936.09 (market cap $108.46B), while Xylem, Inc. trades at $102.11 (market cap $23.81B). The key difference: McKesson Corporation is far larger — about 4.6× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.69%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Xylem, Inc. for 50 Days on average.
| MCK | XYL | |
|---|---|---|
Market Cap | $108.46B | $23.81B |
Volume | 712,607 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $995.69 | $152.95 |
52-Week Low | $725.17 | $100.92 |
Typical Hold Time | 74 Days | 50 Days |
Enterprise Value | $115.00B | $25.59B |
Dividend Yield | 0.4% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $910.33, down 1.23% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue grew to $359.05 billion in 2025, though net margins remain thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing growth visibility in pharmaceutical distribution.
The outlook remains positive given analyst consensus favoring Buy ratings (80.65%) and a price target of $956.43, implying ~5% upside. Risks include margin pressure from drug pricing dynamics and policy uncertainty, while institutional accumulation and solid cash flow generation support stability. Earnings momentum and strategic partnerships position MCK for sustained growth, though investors should monitor competitive and regulatory headwinds.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent revenue growth from $5.5B in 2022 to $9.0B in 2025 and net income margin expanding to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen its industrial water solutions portfolio. XYL has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected on October 27, 2026.
Analyst consensus is mixed with 47.5% buy ratings and a $149.13 price target suggesting 46% upside. Key risks include China market weakness and increased debt from recent acquisitions. The stock offers value with reasonable P/E of 24.28 and strong cash flow generation, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
